35 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Novartis (NVS) Declines More Than Market: Some Information for Investors https://www.zacks.com/stock/news/2245727/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2245727 Mar 25, 2024 - In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.
Novartis (NVS) Stock Dips While Market Gains: Key Facts https://www.zacks.com/stock/news/2242497/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2242497 Mar 18, 2024 - In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089 Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AGFA Gevaert NV (AFGVF) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4678085-agfa-gevaert-nv-afgvf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Mar 13, 2024 - AGFA Gevaert NV (OTCPK:AFGVF) Q4 2023 Earnings Conference Call March 13, 2024 6:00 AM ETCompany ParticipantsPascal Juery - President, CEO, President,...
Novartis (NVS) Stock Dips While Market Gains: Key Facts https://www.zacks.com/stock/news/2239592/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2239592 Mar 12, 2024 - In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.
Novartis (NVS) Advances While Market Declines: Some Information for Investors https://www.zacks.com/stock/news/2238956/novartis-nvs-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2238956 Mar 11, 2024 - Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock https://www.zacks.com/stock/news/2238200/what-makes-mainz-biomed-nv-mynz-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2238200 Mar 08, 2024 - Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
bpost NV/SA (BPOSF) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4675447-bpost-nv-sa-bposf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Mar 01, 2024 - bpost NV/SA (OTCPK:BPOSF) Q4 2023 Earnings Conference Call March 1, 2024 4:00 AM ETCompany ParticipantsChris Peeters - CEOPhilippe Dartienne - CFOConference...
Anheuser-Busch InBev/NV (BUD) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/29/anheuser-busch-inbevnv-bud-q4-2023-earnings-call-t/?source=iedfolrf0000001 Feb 29, 2024 - BUD earnings call for the period ending December 31, 2023.
Roche's (RHHBY) Xolair Gets Approval for Food Allergies https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151 Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

Pages: 1234

Page 1>